Why should every adult get a 3rd shot (booster) when eligible (6 months after 1°💉)? 1. A randomized, placebo-controlled trial, the gold standard for assessing efficacy, showed restoration of efficacy to 95.6%, in >10,000 participants across all age groups
2. Prevention of hospitalizations and deaths in a study of >728,000 people w/ 3-shots vs >728,000 matched controls (2-shots) thelancet.com/journals/lance…@TheLancet
3. We have no US National data by vaxx status but hospitalizations are starting to increase again and several states are reporting an increasing proportion of breakthroughs accounting for them
4. The US is doing a poor job of rolling out boosters relative to many other countries.
Only 1 in 3 people of the highest risk group, age 65+, have received one. Only 1 in 7 overall who are eligible.
5. Despite the compelling data and the current predicament, there is unwarranted and serious division at the top @CDCgov and among some experts who have been in denial of the vaccine effectiveness waning issue for months, resulting in mixed messages to the public and confusion
6. Meanwhile, 2 states have taken the appropriate steps of opening up boosters for all over the age 18 (California and Colorado) which is unprecedented (overriding CDC and FDA). And many countries have made boosters eligible for all adults their policy, including Canada.
7. Getting a booster when there'a a surge in your state is not the best timing ;-)
Also highlights that the booster rate across the US is remarkably low.
8. New data today from the UK shows boosters restore vaccine effectiveness for protection vs symptomatic infection to over 90% (AZ 93%, Pfizer 94%) khub.net/documents/1359… gov.uk/government/new…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We're learning how to control the immune response, like a rheostat, even in the brain. Implications for understanding the basis and potential treatment of autoimmune conditions like multiple sclerosis, #LongCovid, #MECFS, and brain cancer.
A brief review of 6 recent, important reports
in the new Ground Truths, open-access
Such as Programming T cells with brain-specific proteins and payloads
@ScienceMagazine science.org/doi/10.1126/sc…
Or peptide fragments of myelin basic protein that suppress the immune response @Nature nature.com/articles/s4158…
New @NEJM
A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs placebo in a randomized trial of >2,500 participants with obesity, absolute reduction of 10/100 treated
In other GLP-1 new publications today
—Country-wide Sweden reduced hospitalizations for alcohol or substance abuse with these drugs jamanetwork.com/journals/jamap… @JAMAPsych
—Concerns about discontinuation jamanetwork.com/journals/jama/… @JAMA_current
Other new anti-obesity drugs in the pipeline, one that also increases energy expenditure
@NatureNV nature.com/articles/d4158…
A dedicated issue of @ScienceTM on #LongCovid
—Sex-specific differences, with perspective by @VirusesImmunity and @SilvaJ_C
—Insights for therapies @AndreaCoxMDPhD
—Deconvoluting "Osler's Web" @MichaelPelusoMD @DeeksSteven @DrMaureenHanson @SaydahSharon
—+RECOVER Trial, Lyme disease
An elegant @Nature study by @AkassoglouLab has illuminated our understanding of the role of fibrin (component of blood clots), #SARSCoV2, and brain inflammation in Covid and #LongCovid.
This discovery and more in the new Ground Truths podcast, with transcript, key figures (such as as the one below) and citations. Open-access. Link in my profile.
A clip from our conversation. Unknowingly, @AkassoglouLab was gearing up for understanding this complex pathophysiology for many years before Covid hit
For treatment, it's not just as simple as preventing fibrin clots. It's isolating the pro-inflammatory action of fibrin, targeted by the antibody
Covid and increased risk of major adverse cardiovascular events (MACE) 3-years out
2-fold increased for any severity of Covid
~4-fold increase for Covid requiring hospitalization
"a coronary artery disease equivalent"
interaction with non-O blood types
@uk_biobankahajournals.org/doi/10.1161/AT…
"A major finding from our analyses was that the risk
of MACE among the subset of hospitalized COVID-
19 cases without known CVD (ie, primary prevention
patients) was comparable to (or even slightly higher than) the risk in patients with CVD, PAD, or diabetes but without COVID-19."
"one of the first examples of a gene-pathogen exposure interaction for thrombotic events"
I think it's the first one documented, likely others to be unraveled
New US Covid genomic surveillance
The KP.3.1.1 variant is on the move to become dominant, more of a challenge to our immune response than KP.3 and prior variants (especially without new KP.2 booster when we need it for high-risk individuals)
It's the deletion 31/31 that makes the KP.3.1.1 spike different, but otherwise 2 mutations away from KP.2 (R346T and Q493E)
Buckle up; this wave isn't over yet d/t KP.3.1.1's emergence